Trials / Active Not Recruiting
Active Not RecruitingNCT06007677
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Astria Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STAR-0215 | STAR-0215 will be administered as a subcutaneous injection. |
Timeline
- Start date
- 2023-09-26
- Primary completion
- 2031-03-01
- Completion
- 2031-03-01
- First posted
- 2023-08-23
- Last updated
- 2025-07-23
Locations
22 sites across 7 countries: United States, Bulgaria, Canada, Czechia, Germany, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06007677. Inclusion in this directory is not an endorsement.